Q4 revenue increased by 4% to £6.3bn, well in line with our expectations (all growth figures at CER unless specified). As expected, the HIV division reported solid growth (+51%), followed by Vaccines (+20%, -1% at pro-forma) and the Consumer Healthcare segment (+47%; +5% at pro-forma). The non-HIV pharma business continued to languish (-17%, -9% pro forma). Core operating profit declined by 18% to £1.4bn (10% pro forma; margin of 22%), with (before scrapping R&D) HIV margin im
14 Apr 2016
Strong performance by Tivicay, Triumeq, Breo and Anoro
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong performance by Tivicay, Triumeq, Breo and Anoro
GSK plc (GSK:LON) | 1,709 0 0.0% | Mkt Cap: 70,819m
- Published:
14 Apr 2016 -
Author:
Kamla Singh -
Pages:
3
Q4 revenue increased by 4% to £6.3bn, well in line with our expectations (all growth figures at CER unless specified). As expected, the HIV division reported solid growth (+51%), followed by Vaccines (+20%, -1% at pro-forma) and the Consumer Healthcare segment (+47%; +5% at pro-forma). The non-HIV pharma business continued to languish (-17%, -9% pro forma). Core operating profit declined by 18% to £1.4bn (10% pro forma; margin of 22%), with (before scrapping R&D) HIV margin im